{"id":774740,"title":"Comparison of 13-, 15- and 20-valent pneumococcal conjugate vaccines in the paediatric Canadian population, CCDR 51(2/3) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-07","captureTimestamp":"2026-03-07T15:17:18.566000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2025-51/issue-2-3-february-march-2025/comparison-13-15-20-valent-pneumococcal-conjugate-vaccines-paediatric-canadian-population.html","snippet":"Comparison of 13-, 15- and 20-valent pneumococcal conjugate vaccines in the paediatric Canadian population Download this article as a PDF (614 KB) Published by: The Public Health Agency of Canada Issue: Volume 51-2/3, February/March 2025: Health Economics in Public Health Date…","rawSnapshotUrl":"/api/snapshots/raw/774740","browseUrl":"https://replay.healtharchive.ca/job-7/20260307151718/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2025-51/issue-2-3-february-march-2025/comparison-13-15-20-valent-pneumococcal-conjugate-vaccines-paediatric-canadian-population.html#ha_snapshot=774740","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}